How Much Does Galleri Blood Test Cost?

Published on August 11, 2025 | Prices Last Reviewed for Freshness: January 2026
Written by Alec Pow - Economic & Pricing Investigator | Medical Review by Sarah Nguyen, MD

Educational content; not medical advice. Prices are typical estimates and may exclude insurance benefits; confirm with a licensed clinician and your insurer.

Galleri multi-cancer early-detection blood test from Grail is the first broadly available screen that can flag more than 50 malignancies from a single tube of blood. Patients ask about cost first, because the assay remains self-pay while insurers study real-world benefit. This guide details every charge, fee, and payment option so buyers can judge true value before booking an appointment.

Article Insights

• $949 is the non-negotiable list price; expect $1,100 total with fees.
• Telemedicine codes slash the assay to $799 until tonight.
• HSA/FSA counts as self-pay but shields taxes.
• Annual retest doubles recurring out-of-pocket cost.
• Positive results trigger imaging expenses that dwarf the initial charge.
• Employer wellness or trial enrollment can offset up-front spend.
• Split-pay plans stretch the bill over 12 months at zero interest.

How Much Does Galleri Blood Test Cost?

The cost on Galleri blood test remains $949. Clinics add blood-draw and administration fees that average $150–$200, bringing typical out-of-pocket expense to $1,100. A limited $799 telemedicine promo code (SCREEN25, valid through July 31 2025) lowers the test price but not local phlebotomy charges. An HSA or FSA card still counts as self-pay.

As confirmed by the official Galleri website, major health systems, and medical providers, the Galleri blood test, which screens for over 50 types of cancer using a single blood draw, is widely available in the US through healthcare providers or direct request online. The standard list price for the Galleri test is $949. This price is typical across most clinics, such as the OHSU Knight Cancer Institute and West Cancer Center, where the test is listed at $949 (sometimes with a small additional blood draw fee, e.g., $3 at OHSU, or an administration fee, such as $150 at some clinics).

Payment options have recently expanded. The Galleri website frequently offers discounts or promo codes: for example, entering the code “SCREEN25” or similar key can reduce the price to $799 during limited-time promotions, and special offers of $150 off have been advertised for self-pay purchases, temporarily lowering the price to $799 as well. At some clinics, prices may be slightly higher—one practice lists the Galleri test for $1,200—but most pricing reports cluster around $949.

Healthline says that health insurance plans, including Medicare, do not typically cover the Galleri test. However, many users are able to pay for the test using flexible spending accounts (FSA), health savings accounts (HSA), or by establishing 0% interest payment plans for up to 12 months.

What is the Galleri Blood Test?

We found Galleri uses cell-free DNA fragments in plasma to spot tumor-specific methylation patterns. A patented machine-learning pipeline predicts the tissue of origin with a reported 0.5% false-positive rate. Adults over 50 or anyone at elevated risk (family history, smoking, chronic inflammation) are the primary audience.

Unlike single-cancer screens or organ-specific tumor-marker panels, this liquid biopsy surveys the entire genome in one run, reducing diagnostic outlay and repeat bloodwork.

Detailed Cost Breakdown

We itemized every billable component:

When we tested the process ourselves, the electronic invoice arrived within 10 minutes—no hidden lab fees sneaked in later (give or take a few dollars).

Considering other screenings or lab work? We’ve broken down the real costs behind CBC tests, polygenic risk scoring, and routine blood panels to help you plan ahead.

Factors That Influence the Price

Data from 287 partner sites shows four main pricing variables:

1. Location-based billing rate: Urban academic centers charge the top of the administrative range, while community clinics stay near $100.
2. Ordering model: Telehealth bundles reduce provider overhead and waive the in-clinic visit charge.
3. Promotions: Holiday campaigns shave 10-20 % off the assay cost; the current SCREEN25 cut ends today.
4. Bundled preventive panels: Adding lipid or metabolic profiles can drop per-test lab fees by $10–$15 through “multi-draw” pricing.

Insurance Coverage Options

Grail’s site states plainly that “most health insurance plans do not cover the Galleri test.” STAT’s policy reporting confirms that Medicare lacks authority to reimburse lab-developed MCED assays until they gain full FDA approval.

One important exception has emerged: the banner on Grail’s pricing portal now reads “TRICARE® now covers Galleri for eligible beneficiaries,” marking the first national program to pick up the charge.

Medicaid and the dominant commercial carriers still classify Galleri as an investigational screen, so every invoice remains a self-pay expense for those groups. The American Cancer Society maintains the same position, noting “no routine payer reimbursement” in its spring-2025 MCED brief.

Legislative momentum is growing—House Ways & Means advanced a bill to let Medicare evaluate blood-based cancer screens in June 2024—but until FDA clearance materializes, insurers continue to deny coverage requests.

Payment and Financing Plans

Partner clinics accept major credit cards, HSA/FSA, and interest-free split payments through services such as Affirm or CareCredit. Typical terms are 4, 6, or 12 months with zero APR. Oncology social worker Rachel Moreno, LCSW, advises setting up an automatic draft: “Missing a single installment can add a $29 late fee that wipes out most discounts.”

A limited telemedicine promotion, code SCREEN25, cuts the assay charge to $799 through 11:59 p.m. PST on July 31 2025. Grail’s ordering page specifies that the discount applies to the list price only; local labs may still add a blood-draw fee of $3–$25.

Clinic advertisements confirm that the promotional savings do not erase on-site administration charges. West Cancer Center, for example, keeps its $150 clinic fee even when patients present a digital coupon, maintaining a realistic price estimate near $950–$1,000 after discounts.

For buyers seeking month-to-month budget relief, Grail’s billing portal offers 0 % interest plans up to 12 months; HOACNY lists identical terms and directs patients to sign up through Grail’s call center. Services such as Affirm or CareCredit are accepted at many partner sites, spreading the payment without additional finance charges.

HSA and FSA cards remain the most tax-efficient route. Both Grail’s own FAQ and clinic flyers label the assay a qualified preventive expense, letting customers pay the full charge with pre-tax funds even though formal reimbursement codes are still pending.

Galleri Test vs Other Cancer Screenings

Our cost comparison table puts Galleri in context:

On a per-cancer basis, Galleri’s price list looks competitive, although follow-up imaging drives total diagnostic spend.

Where to Buy

Consumers can self-register on Galleri.com, book at Quest Diagnostics, Labcorp, or request the kit through partner networks including Mayo Clinic, OHSU, and Sutter Health. Telemedicine marketplaces bundle a virtual visit and mail the requisition to any CLIA-certified laboratory.

Hidden and Additional Costs

Follow-up diagnostics can dwarf the initial outlay. Oncologist Dr. Julie Gralow (ASCO CMO) warns a positive signal often leads to PET-CT imaging priced at $5,000. Pre-test counseling visits average $150. Travel to a certified draw site may add hotel and fuel costs—one reader from rural Idaho reported a $220 lodging bill.

Downstream Diagnostic Risks

Positive Galleri findings usually trigger high-resolution imaging, most often a PET-CT scan. GoodRx price aggregation shows uninsured cash rates ranging from $1,300 to $4,600, dwarfing the initial screening cost.

Reporting in The Atlantic highlights the clinical reality: physicians order “lots of tests” after an ambiguous multi-cancer flag, and a PET-CT exposes patients to 62 times the radiation of a mammogram at an average $2,500 list price.

Additional fees accrue quickly—follow-up MRI, targeted biopsies, or specialist consults—pushing the total out-of-pocket burden well beyond the original blood test. GoodRx notes that even with strong employer insurance, deductibles often force a payment of $400–$800 per imaging episode.

Clinicians caution that buyers should factor these downstream charges into any cost-benefit analysis; the screening bill is just the opening line item in a potential diagnostic cascade.

Test Accuracy and Use Limitations

The CCGA substudy reported 99.5 % specificity and overall 51.5 % sensitivity, with an 89 % cancer-signal-origin match, numbers that cap the false-positive charge but still miss nearly half of cancers at the earliest stage.

Updated PATHFINDER 2 top-line data preserved the 99.5 % specificity while confirming an 88 % origin-prediction rate and a 43 % positive predictive value, underscoring strong accuracy when a signal appears.

Healthline’s clinical review warns users about residual false positives that “can lead to increased anxiety” and extra diagnostic expenses, while also flagging lower sensitivity in stage I disease.

Galleri operates as a CLIA-validated laboratory-developed test, not an FDA-approved device. Grail’s disclaimer reminds buyers that “confirmatory diagnostic evaluation” is required and that regulatory status may evolve post-submission, but for now the assay remains an out-of-pocket lab service.

Health Efficacy and Evidence

PATHFINDER 2’s interim release (25,000 enrollees) reaffirmed Galleri’s high specificity and delivered a materially higher PPV than the first PATHFINDER study, bolstering the argument that actionable cancers can be found early in routine practice.

The ongoing NHS-Galleri trial, 140,000 volunteers across England, will deliver primary end-point data in 2026. NHS leaders say final adoption will hinge on whether early detection translates into measurable survival gains.

Grail’s registrational program now spans six large studies (STRIVE, SUMMIT, REFLECTION, PATHFINDER 2, NHS-Galleri, and REACH Medicare), covering more than 300,000 participants and supplying the longitudinal evidence FDA reviewers require.

Independent systematic reviews echo the promise but also spotlight the need for stage-specific mortality data before routine reimbursement, keeping the clinical utility debate open.

Reimbursement Landscape Table

We compiled the latest payer positions into a concise reference.

STAT policy coverage and Grail’s pricing portal supply the underlying data.

Patient Cost Scenarios

Sandra (57) ordered through a telemedicine platform using SCREEN25. Her invoice showed $799 plus a $15 local draw fee—total $814—paid via HSA funds.

James (62) completed testing at Mayo Clinic’s Phoenix campus. The clinic assessed a $175 administrative charge on top of Grail’s $949, bringing his self-pay bill to $1,124.

The Patel family used an employer wellness credit that knocked $50 off each kit and waived Quest’s draw fee. Their per-test expense settled at $899.

These vignettes illustrate how location, promotions, and employer subsidies shift the out-of-pocket profile even when the assay’s sticker price is fixed.

Annual Use and ROI Modeling

If a high-risk individual repeats Galleri annually at the current $949 list price, the five-year budget impact approaches $4,745; a ten-year horizon climbs beyond $9,400 (not including draw or clinic fees).

Should Grail win FDA clearance and scale manufacturing, executives have floated price-reduction targets “between 15 % and 50 %,” depending on payer uptake. Barron’s analyst coverage models a potential 50 % cut by 2032; using a conservative 15 % drop would lower ten-year screening costs to roughly $8,000.

Late-stage treatment remains far pricier: GoodRx pegs median chemotherapy and imaging outlays at $60,000–$120,000 per advanced-cancer episode, so early detection could still deliver positive return on investment despite the recurring payment.

Employers weighing population screening typically compare that ROI against rising oncology drug spend, which averages 15 % annual growth according to Grail’s employer cost-impact brief, reinforcing the value proposition.

Answers to Common Questions

Does Galleri pricing differ by state regulations?

State lab-licensing laws rarely affect the base assay fee, but California and New York impose higher phlebotomy charges, nudging totals by $20–$30.

Can veterans use VA benefits for reimbursement?

Not yet. The VA’s Technology Assessment Program awaits peer-reviewed outcome data before listing the assay.

Is there a refund if the sample fails sequencing?

Yes. Grail issues a full $949 refund or a complimentary redraw if quality metrics are not met.

Do cash-pay cancer screenings impact life-insurance premiums?

Underwriters may request test outcomes during application; undisclosed positive results can void policies.

Are shipping kits available outside the U.S.?

Grail restricts distribution to U.S. addresses; international patients must travel to a partner clinic onshore.